Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I1/57

[1] Hirohama D, Shimizu T, Hashimura K, et al. Reversible respiratory failure due to rhabdomyolysis associated with cytomegalovirus infection[J]. Intern Med, 2008, 47(19)：1743-1746.
[2] Kumar A A, Bhaskar E, Palamaner Subash Shantha G, et al. Rhabdomyolysis in community acquired bacterial sePsis-a retrospective cohort study[J]. PLoS One, 2009, 4：e7182.
[3] Allison R C,Bedsole D L. The other medical causes of rhabdomyolysis[J]. Am J Med Sci,2003, 326(2): 79-88.
[4] 李瑞珍, 陈飞苑,陈伟兰. 436 例异烟肼致不良反应文献分析[J]. 中国药房, 2007, 18(8): 620-622.
[5] Mark H Beers.默克诊疗手册[M]. 北京: 人民卫生出版社, 2002.
[6] 杨建国. 左氧氟沙星致跟腱炎2例[J]. 医药导报,2005, 24(9): 801-802.
[7] 刘妍, 李青. 355例左氧氟沙星不良反应的文献分析[J]. 中国医药指南, 2013, 11(9): 250-252.
[8] 李中东. 左氧氟沙星的不良反应[J]. 药物不良反应杂志, 2003,3(1): 25.
[9] Sauret J M, Marinides G, Wang G K. Rhabdomyolysis[J]. Am Fam Physician, 2002,65(5): 907-12.
[10] 何仙梅,宿燕岗. 左氧氟沙星引起横纹肌溶解症一例[J]. 中华内科杂志, 2001, 40(12): 880.
[11] Baril L, Maisonobe T, Jasson-Molinier M, et al. Acute rhabdomyolysis during treatment with ofloxacin-a case report[J]. Clin Infect Dis. 1999, 29(6): 1598-1599.
[12] Gupta A, Guron N, Harris M, et al . Levofloxacin-induced rhabdomyolysis ina hemodialysis patient[J]. Hemodial Int. 2012, 16(1): 101-103.
[13] Korzets A, Gafter U, Dicker D, et al. Levofloxacin and rhabdomyolysis in a renal transplant patient[J]. Nephrol Dial Transplant. 2006, 21(11): 3304-3305.
[14] Petitjeans F, Nadaud J, Perez J P, et al. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin[J]. Eur J Clin Pharmacol,2003, 59(10): 779-780.
[15] Hirohisa Nakamae M H, Yamane T, Ohta K, et al. A Case of Rhabdomyolysis due to Levofloxacin[J]. Clin Drug Investig, 2000, 20(3): 203-205.
[16] Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treated with oloxacin and fedanormal or magnesium-dificientdiet[J]. Antimicrob Agents Chemother. 2000, 44(2): 261-266.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.